Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07644442
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmedCompletedPhase 1
NCT07644442Completed
Phase 1
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmed
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07646314
Comparative Effects of Post-Isometric Relaxation and Reciprocal Inhibition Techniques inPiriformis SyndromeRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646314Not Yet Recruiting
Not Applicable
Comparative Effects of Post-Isometric Relaxation and Reciprocal Inhibition Techn...Riphah International Univ...
NCT07645079
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes CareSteno Diabetes Center CopenhagenNot Yet RecruitingNot Applicable
NCT07645079Not Yet Recruiting
Not Applicable
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes CareSteno Diabetes Center Cop...
NCT07644936
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisNot Yet Recruiting
NCT07644936Not Yet Recruiting
—
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Speci...
NCT07645339
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier RepairL'OrealActive Not RecruitingNot Applicable
NCT07645339Active Not Recruiting
Not Applicable
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier...L'Oreal
NCT07644013
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First HospitalRecruiting
NCT07644013Recruiting
—
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First H...
NCT07644312
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNationwide Children's HospitalNot Yet RecruitingPhase 2
NCT07644312Not Yet Recruiting
Phase 2
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG...Nationwide Children's Hos...
NCT07645170
Strain Counter-Strain vs Maitland Mobilization for Sacroiliac Joint PainUniversity of FaisalabadActive Not RecruitingNot Applicable
NCT07645170Active Not Recruiting
Not Applicable
Strain Counter-Strain vs Maitland Mobilization for Sacroiliac Joint PainUniversity of Faisalabad
NCT07645248
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)GlaxoSmithKlineNot Yet RecruitingPhase 3
NCT07645248Not Yet Recruiting
Phase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1...GlaxoSmithKline
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07646002
Effectiveness of Balloon Blowing and Deep Breathing Exercise on Increasing Peripheral Oxygen Saturation in Patients With Chronic Obstructive Pulmonary DiseaseIndonesia UniversityCompletedNot Applicable
NCT07646002Completed
Not Applicable
Effectiveness of Balloon Blowing and Deep Breathing Exercise on Increasing Perip...Indonesia University
NCT07645560
A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic StrokeBeijing Tiantan HospitalNot Yet RecruitingPhase 2
NCT07645560Not Yet Recruiting
Phase 2
A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After...Beijing Tiantan Hospital
NCT07644767
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty LtdNot Yet RecruitingPhase 2
NCT07644767Not Yet Recruiting
Phase 2
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty Lt...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646132
Focal Extracorporeal Shock Wave Therapy With Two Different Dosing Regimens for Chronic Low Back PainArmando Tonatiuh Avila GarciaNot Yet RecruitingNot Applicable
NCT07646132Not Yet Recruiting
Not Applicable
Focal Extracorporeal Shock Wave Therapy With Two Different Dosing Regimens for C...Armando Tonatiuh Avila Ga...
NCT07645378
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South AfricaCentre for the AIDS Programme of Research in South AfricaNot Yet RecruitingNot Applicable
NCT07645378Not Yet Recruiting
Not Applicable
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervica...Centre for the AIDS Progr...
NCT07646405
Combined Effects of NMES and LIRT on Muscle Strength, Girth, and Physical Endurance in the Geriatric PopulationRiphah International UniversityRecruitingNot Applicable
NCT07646405Recruiting
Not Applicable
Combined Effects of NMES and LIRT on Muscle Strength, Girth, and Physical Endura...Riphah International Univ...
Result Breakdown
Not yet recruiting12 (60%)
Recruiting4 (20%)
Completed2 (10%)
Active, not recruiting2 (10%)
not_applicable8 (40%)
Not Specified4 (20%)
Phase 24 (20%)
Phase 12 (10%)
Phase 31 (5%)
Phase 41 (5%)